Hiroaki Ueno, former president of the Japan Pharmaceutical Manufacturers Association (JPMA), has taken up a newly created post at the Japan Agency for Medical Research and Development (AMED), effective January 1. According to AMED, Ueno was named special adviser to…
To read the full story
Related Article
- AMED, JPMA Poised to Embed Pharma Expertise in Drug Discovery
January 20, 2026
REGULATORY
- Japan Drug Prices to Fall 4% in FY2026 Revision: Official Gazette
March 5, 2026
- Romiplate to See Steepest Cut in April Market Expansion Re-Pricing
March 5, 2026
- MHLW Clarifies Use of Real-World Data in Drug Applications
March 5, 2026
- MHLW Expands Eligibility for “Specific-Use Drug” Designation
March 5, 2026
- MHLW to Launch Priority Review Pathway for Overseas Alternatives amid Drug Shortages
March 5, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





